Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
Recruiting
N/A
Interventional Study
NonHodgkin Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 840 (estimated)
- Sponsor
- Tata Memorial Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions.
The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement in overall survival and progression free survival with combined modality treatment. The doses of ra…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histological Diagnosis of NHL- DLBCL.
* Eligible for RT after R-CHOP.
* ECOG 0-3.
* 18 - 65 years.
* Stage I-IV.
* Patients should receive at least 4 cycles of R-CHOP chemotherapy.
* Patients with all extranodal disease except the ones mentioned in the exclusion criteria.
* Ab…
Contacts